Trial intelligence / Profile preview

Aztreonam Lysinate for Inhalation in Cystic Fibrosis (AIR-CF1)

NCT00112359Phase 3Completed

Sponsor
Gilead Sciences
Start
May 2005
Primary completion
Apr 2007
Modality
Inhalation Devices, Small Molecules
Countries
4
01

Overview

A Phase 3 trial of aztreonam in cystic fibrosis (CF), sponsored by Gilead Sciences. Started May 2005; status: completed.

02

Drugs

aztreonam
03

Conditions

cystic fibrosis (CF)

Beyond the preview

Go deeper on NCT00112359.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on NCT00112359.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call